21st week of 2014 patent applcation highlights part 48 |
Patent application number | Title | Published |
20140142009 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 2014-05-22 |
20140142010 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 2014-05-22 |
20140142011 | Lubricant Compositions Comprising Epoxide Compounds - A lubricant composition including an epoxide compound is disclosed. An additive package including the epoxide compound is also disclosed. The epoxide compound of the lubricant composition acts to improve compatibility of the lubricant composition with a fluoropolymer seal and improve the total base number of the lubricant composition. | 2014-05-22 |
20140142012 | GREASE COMPOSITION FOR EV/HEV DRIVING MOTOR BEARING AND EV/HEV DRIVING MOTOR BEARING - A grease composition for EV/HEV driving motor bearing, containing a diurea thickener of the following formula (A): | 2014-05-22 |
20140142013 | MONOESTER-BASED LUBRICANTS AND METHODS OF MAKING SAME - The present invention is generally directed to monoester-based lubricant compositions. The present invention is also directed to methods of making these and other similar lubricant compositions. In some embodiments, the methods for making such monoester-based lubricants utilize a biomass precursor and/or low value Fischer-Tropsch (FT) olefins and/or alcohols so as to produce high value monoester-based lubricants. In some embodiments, such monoester-based lubricants are derived from FT olefins and fatty acids. The fatty acids can be from a bio-based source (i.e., biomass, renewable source) or can be derived from FT alcohols via oxidation. | 2014-05-22 |
20140142014 | ESTOLIDE AND LUBRICANT COMPOSITIONS THAT CONTAIN ENE AND DIELS ALDER COMPOUNDS - Provided herein are compositions containing at least one estolide compound and at least one ene and/or Diels Alder compound. In certain embodiments, the addition of at least one ene and/or Diels Alder compound to an estolide-containing composition may improve the cold temperature, viscometric, and/or anti-wear properties of the composition. | 2014-05-22 |
20140142015 | SOLVENT EXTRACTION FOR PREPARING A SALT OF A SULFURIZED ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION - Disclosed is a process for preparing a salt of a sulfurized alkyl-substituted hydroxyaromatic composition having a reduced content of unsulfurized alkyl-substituted hydroxyaromatic compound and its unsulfurized metal salt. The process involves at least the steps of: (a) providing a composition comprising (i) a salt of a sulfurized alkyl-substituted hydroxyaromatic compound; (ii) an unsulfurized alkyl-substituted hydroxyaromatic compound and (iii) an unsulfurized metal salt of the alkyl-substituted hydroxyaromatic compound; wherein the alkyl-substituted hydroxyaromatic compound is derived from alkylation of a hydroxyaromatic compound with one or more olefins comprising C | 2014-05-22 |
20140142016 | SKIN CLEANSING AGENT COMPOSITION - A skin cleansing agent composition of the present invention contains an isotropic liquid phase, which is a bicontinuous structure, and containing: 15 to 30 mass % of a nonionic surfactant having HLB of higher than 9 and equal to or lower than 20; 1 to 15 mass % of a nonionic surfactant having HLB of equal to or higher than 5 and equal to or lower than 9; 10 to 40 mass % of an oil agent exhibiting a viscosity at 30 degrees C. of equal to or lower than 30 mPa·s; 10 to 40 mass % of a water-soluble solvent having 3 or more of hydroxyl groups in single molecule; 10 to 30 mass % of a water-soluble solvent having 1 or 2 hydroxyl group(s) in single molecule; 0.05 to 1.0 mass % of a water-soluble polymer containing (meta)acrylic acid as a configuration unit and/or an acryloyl methyl taurate-vinylpyrrolidone copolymer; 0.001 to 2.0 mass % of a water-soluble inorganic salt and/or an organic salt having 1 to 8 carbon atoms; and water. | 2014-05-22 |
20140142017 | Process And Composition For Removing Substances From Substrates - Compositions are described that are useful for removing organic and organometallic substances from substrates, for example, photoresist wafers. Processes are presented that apply a minimum volume of a composition as a coating to the inorganic substrate whereby sufficient heat is added and the organic or organometallic substances are completely removed by rinsing. The compositions and processes may be suitable for removing and, in some instances, completely dissolving photoresists of the positive and negative varieties, and specifically negative dry film photoresist from electronic devices. | 2014-05-22 |
20140142018 | EXTRUSION OR INJECTION MOLDING MACHINE PURGING COMPOSITION AND METHOD - A composition comprising 10-80% by weight of a cellulose ether and a solvent selected from a water-soluble polyhydric alcohol, polyhydric alcohol ether, polyhydric alcohol ester, and ethanolamine is effective for purging extrusion and injection molding machines. The purging composition exerts a satisfactory purging or cleaning effect, but little abrasion effect, thus avoiding any abrasion of machine internal components by purging. Even if part of the purging composition is left within the machine after the composition is discharged out, the residue can be readily removed. | 2014-05-22 |
20140142019 | FABRIC TREATMENT COMPOSITIONS COMPROSING TARGETED BENEFIT AGENTS - The invention provides a benefit agent delivery particle comprising hydroxylpropyl cellulose. The benefit agent delivery particle may further comprise a non-polysaccharide polymer, preferably an aminoplast polymer. The benefit agent delivery particle may comprise a perfume. The invention also provides a process for the manufacture of the particles in which perfume oil is encapsulated using emulsion polymerization to form core-shell particles, (in the alternative the perfume may be adsorbed later) and, a further polymer layer is formed on the outer surface of the core shell-particles in the presence of the delivery aid. | 2014-05-22 |
20140142020 | PARTICLE DEFOAMER AND PROCESS FOR PREPARING SAME - A process for preparing a particle defoamer. The particle defoamer of 55%-75% of a carrier, 15%-35% of a silicone emulsion, 3%-10% of a texturing agent and 2%-10% of a solvent, based on the total weight of the particle defoamer; the process for preparing the particle defoamer is: (1)first adding a carrier A1 into a mixer, and then adding thereto a silicone emulsion B1, and stirring uniformly; (2)adding a carrier component A2 to the mixture obtained in (1), and stirring uniformly; (3)adding a silicone emulsion B2 to the mixture obtained in (2), and, after uniformly stirring, adding the solvent thereto and stirring uniformly; and (4)pelleting and drying by baking the mixture obtained in(3), so as to produce the product. | 2014-05-22 |
20140142021 | RECONSTITUTED PULMONARY SURFACTANTS - The present invention is directed to a reconstituted surfactant comprising a phospholipid mixture, and a combination of particular analogues of the native surfactant protein SP-C with analogues of the native surfactant protein SP-B. The invention is also directed to pharmaceutical compositions and kits thereof and to its use for the treatment or prophylaxis of RDS and other respiratory disorders. | 2014-05-22 |
20140142022 | SYNTHETIC APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE - The invention provides a synthetic polypeptide of Formula I′: | 2014-05-22 |
20140142023 | Pharmaceutical Composition for Treating A Metabolic Syndrome - The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 2014-05-22 |
20140142024 | BPI AND ITS CONGENERS AS RADIATION MITIGATORS AND RADIATION PROTECTORS - Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy. | 2014-05-22 |
20140142025 | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent - The disclosure describes collagen constructs comprising antimicrobial agents and related methods. | 2014-05-22 |
20140142026 | Anti-Pathogen Treatments - Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain, and their methods of use in preventing or treating a pathogen infection in a cell or organism are described. The pathogen-detection domain and effector domain of the chimeric molecules are domains not typically found in nature to be associated together. Agents are also described herein having at least one pathogen-interacting molecular structure and at least one effector-mediating molecular structure, the agent being one that is non-naturally-occurring in a cell. The methods of prevention and treatment described herein are effective for a broad spectrum of pathogens and exhibit little or no toxic side-effects. Assays for the detection of a pathogen, pathogen component, or product produced or induced by a pathogen, are also provided. | 2014-05-22 |
20140142027 | MULTIMERIC FORMS OF ANTIMICROBIAL PEPTIDES - The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. The method includes a composition or combination comprising the multimeric antimicrobial peptides and at least one active pharmaceutical ingredient. | 2014-05-22 |
20140142028 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 2014-05-22 |
20140142029 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 2014-05-22 |
20140142030 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms. The invention also relates to a method of treating a subject for a gram-negative bacterial infection by administering a polymyxin derivative of the invention in combination with a second antibacterial agent. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 2014-05-22 |
20140142031 | CYCLIC PEPTIDE FROM NONOMURAEA SP., PROCESS FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MYCOBACTERIA RELATED DISEASE COMPRISING THE SAME - The present invention relates to novel anti-TB cyclic peptides from | 2014-05-22 |
20140142032 | Caspofungin Acetate Formulations - A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture. | 2014-05-22 |
20140142033 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 - Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1. | 2014-05-22 |
20140142034 | Unkown - The invention relates to a composition in aqueous solution, including insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1≦u≦8) of identical or different saccharide units, linked via identical or different glycoside bonds, said saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. The invention also relates to a pharmaceutical formulation comprising a composition as claimed in any one of the preceding claims. | 2014-05-22 |
20140142035 | METHODS AND COMPOSITIONS FOR MODULATING INSULIN REGULATION - The present invention provides a combination of compounds capable of modulating xenin activity and, insulin secretion and weight gain. The invention also provides methods for modulating GIP activity and insulin secretion in a subject, by modulating xenin activity in the subject. | 2014-05-22 |
20140142036 | DIPEPTIDYL PEPTIDASE-4 INHIBITOR - The present invention aims to provide a DPP-4 inhibitor that is obtained by using a food as a raw material and that is suitable for oral ingestion from the viewpoints of flavor and absorbability, and a composition for the prevention and/or amelioration of diabetes which contains the DPP-4 inhibitor. The present invention provides a DPP-4 inhibitor obtained by treating an azuki bean or a kidney bean with a microorganism or a proteolytic enzyme produced by the microorganism. In particular, a preferable DPP-4 inhibitor can be obtained by hydrolyzing an azuki bean with a koji mold or a proteolytic enzyme derived from the koji mold to fragment a protein in the azuki bean. | 2014-05-22 |
20140142037 | SITE-DIRECTED MONO-SUBSTITUTED PEGYLATED EXENDIN ANALOG AND PREPARATION METHOD THEREFOR - The invention discloses site-specific mono-PEGylated Exendin analogs in which any amino groups can be mono-PEGylated as well as their preparation method and use. The method of the present invention adopts a more stable protective group Dde (N-α-1-(4,4-dimethyl-2,6-dioxo-cyclohexylene)) to avoid multi-PEGylated side reactions rendered by unstable protecting groups, achieving mono-PEGylated Exendin analogs at a high recovery with a low reaction molar ratio. | 2014-05-22 |
20140142038 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 2014-05-22 |
20140142039 | Vasoactive lntestinal Peptide Release From Microparticles - Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group. | 2014-05-22 |
20140142040 | Heparin/Heparan Sulfate-Dependent Inhibitors of Activated Protein C and Uses Thereof in Treating Hemophilic Disorders - Methods for inhibiting activated protein C (APC) comprising contacting the APC with a Kunitz polypeptide in an amount effective in inhibiting the activity of APC, wherein the Kunitz polypeptide comprises six cysteine residues at positions corresponding to positions 7, 16, 32, 40, 53, and 57 in SEQ ID NO:1, a motif X | 2014-05-22 |
20140142041 | Cross-linked collagen comprising metallic anticancer agents - The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods. | 2014-05-22 |
20140142042 | SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS - A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars. | 2014-05-22 |
20140142043 | INHIBITION OF DRUG RESISTANT CANCER CELLS - Provided herein are methods of treating cancer in a cancer patient by overcoming resistance of a cancer cell to a drug, or methods of overcoming resistance of a cancer cell to a drug, comprising administering to the patient an effective amount of (i) an EGFR tyrosine kinase inhibitor or a B-Raf kinase inhibitor, and (ii) an HDAC inhibitor. Also provided are methods for inhibiting or preventing proliferation of drug tolerant persister (DTP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. Yet also provided are methods for inhibiting or preventing formation of colonies of drug tolerant expanded persister (DTEP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. | 2014-05-22 |
20140142044 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds. The compounds of the invention have potential therapeutic activity in view of their binding and inhibitory activities towards Plk1. They are based on the amino acid sequence PLHSpT (phosphorylated Thr). The PEG moiety, when present, is covalently attached at the N-terminus. The invention also encompasses derivatives having substituents on the Pro and/or the His side chains, substituents on the phosphate group, the replacement of His with Gln, the replacement of Pro with a N-substituted Gly, the replacement of Ser with Ala, as well as HS-pT fragments with N-terminal alkoxycarbonyl group and PLHS fragments with a C-terminal glyco-imino-alkylxyalkylamide group. | 2014-05-22 |
20140142045 | USE OF REGULATOR OF CALCINEURIN 1 FOR MANUFACTURING MEDICAMENT FOR TREATMENT OF DISEASES ASSOCIATED WITH INCREASED NF-KB ACTIVITY - The present invention provides the use of a peptide comprising an amino acid sequence of SEQ ID NO:3, or the encoding nucleic acid thereof, for manufacturing medicament for treatment of diseases associated with increased NF-κB activity. The peptide can interact with IKB and influence phosphorylation of IKB in the tyrosine at position 42, thereby inhibiting the signal pathway of NF-κB. | 2014-05-22 |
20140142046 | NOVEL WNT COMPOSITIONS AND THERAPEUTIC USES OF SUCH COMPOSITIONS - The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth. | 2014-05-22 |
20140142047 | POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample. | 2014-05-22 |
20140142048 | FIBROUS PROTEIN FUSIONS AND USE THEREOF IN THE FORMATION OF ADVANCED ORGANIC/INORGANIC COMPOSITE MATERIALS - The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation. | 2014-05-22 |
20140142049 | PEGYLATED APELIN AND USES THEREOF - The invention provides compositions and methods for treating a disease or disorder associated with Apelin. Specifically, the invention relates to a pegylated form of Apelin to provide extended circulating life and inotropic effects, and thereby efficiently treat diseases or disorders associated with Apelin. | 2014-05-22 |
20140142050 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES - The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions. | 2014-05-22 |
20140142051 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE - The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably L-glutamine; a dipeptide capable of releasing glutamine, L-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine; an oligopeptide consisting of two to seven glutamine, preferably L-glutamine residues; and mixtures thereof. The peritoneal dialysis fluids of the present invention are useful for inhibition of technical failure in a person undergoing peritoneal dialysis treatment. | 2014-05-22 |
20140142052 | PHOSPHORYLATED POLYOLS, PYROPHOSPHATES, AND DERIVATIVES THEREOF HAVING BIOLOGICAL ACTIVITY - The present invention provides phosphorylated and pyrophosphate derivatives of polyols, and structural derivatives of these compounds, and provides pharmaceutical compositions comprising the same. The compounds and compositions disclosed herein have various biological activities, including for example, as allosteric effectors of hemoglobin and/or as kinase inhibitors. The present invention further provides methods for therapy in human or mammalian patients, and methods for synthesis of biologically active compounds and their intermediates. | 2014-05-22 |
20140142053 | Use of a Composition Comprising Acylated Steryl Glucoside in the Manufacture of a Product - The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-density lipoprotein receptor, apolipoprotein-A1, superoxide dismutase-2, and catalase, characterised in that: the composition comprising acylated steryl glucoside. | 2014-05-22 |
20140142054 | ARTHROPOD PEST CONTROL COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS - Disclosed is an arthropod pest control composition having an excellent controlling effect on arthropod pests, which comprises an amide compound represented by formula (a), a spinosin compound represented by formula (1), wherein R | 2014-05-22 |
20140142055 | METHODS OF TREATING RECURRENT MEIBOMIAN GLANDS DISORDER AND THEREBY DECREASING THE FREQUENCY OF RECURRENCE - A method of treating a recurring meibomian gland disorder in a patient includes administering to a patient suffering from recurring meibomian gland disorder a composition comprising a therapeutically effective amount of an azalide antibiotic and a glucocorticoid. The method may thereby reduce the frequency of recurrence of the meibomian gland disorder. | 2014-05-22 |
20140142056 | METHODS OF TREATING CANCER WITH GLUT INHIBITORS AND OXIDATIVE PHOSPHORYLATION INHIBITORS - Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor. | 2014-05-22 |
20140142057 | EFFECTIVE TREATMENT OF OVARIAN CANCER USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art aid experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. The invention further encompasses a number of miRNAs, which are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, -199a*, -200a, -100, -12Sb, and let-7 cluster. Further, the invention illustrates that frequent deregulation of miR-214, -199a*, -200a and -100 in ovarian cancers and their alterations are associated with high grade and late stage tumor. | 2014-05-22 |
20140142058 | DOSING REGIMENS FOR TREATMENT OF PROLIFERATIVE DISORDERS COMPRISING ADMINISTRATION OF SAPACITABINE - One aspect of the present invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating a proliferative disorder, wherein the sapacitabine or metabolite thereof is administered in a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle comprises administering a therapeutically effective amount of sapacitabine or metabolite thereof for about 2 to about 6 days per week, for 2 weeks out of 3 weeks. Another aspect of the invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating cutaneous T-cell lymphoma (CTCL). | 2014-05-22 |
20140142059 | THERAPEUTIC SUBSTANCES THAT MODULATE GENOME METHYLATION - Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expression and altered pattern of epigenomic control. These compounds, when used as nutrients or in other medicinal application methods, can alter the DNA methylation pattern in a simple way through the well-understood mechanism of kinetic isotope effect (KIE). This effect could also be useful for modifying methylation kinetics in stem cell technology, cloning and as disease therapeutics. | 2014-05-22 |
20140142060 | METHOD AND DEVICE FOR IDENTIFICATION OF ONE CARBON PATHWAY GENE VARIANTS AS STROKE RISK MARKERS, COMBINED DATA MINING, LOGISTIC REGRESSION, AND PATHWAY ANALYSIS - The disclosure provides method and device using a whole genome association analysis toolset for a total stroke case, versus a control group, which demonstrated significant associations with p less than 1.00E.03 for 5 genes, including polymorphisms in MTHFR, MTRR, and BHMT. These gene polymorphisms in MTHFR may remove or create intron and exon splice enhancer sites that affect alternative splicing activity as well as appropriate mRNA and protein production. | 2014-05-22 |
20140142061 | OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME - The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome. | 2014-05-22 |
20140142062 | PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISING HYALURONIC ACID AND TREATMENT OF DERMATOLOGICAL CONDITIONS THEREWITH - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 2014-05-22 |
20140142063 | HYDROGEL TISSUE ADHESIVE HAVING DECREASED GELATION TIME AND DECREASED DEGRADATION TIME - A hydrogel tissue adhesive having decreased gelation time and decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide containing aldehyde groups with a water-dispersible, multi-arm amine in the presence of a thiol additive. The thiol additive accelerates the process to form the hydrogel and accelerates the degradation of the hydrogel formed. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery. | 2014-05-22 |
20140142064 | BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. | 2014-05-22 |
20140142065 | METHOD OF USING BINUCLEAR GOLD (I) COMPOUNDS FOR CANCER TREATMENT - Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo. | 2014-05-22 |
20140142066 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING EYE PATHOLOGIES - The present invention relates to pharmacology, medicine, ophthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy. | 2014-05-22 |
20140142067 | TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF - The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto. | 2014-05-22 |
20140142068 | TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF - The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto. | 2014-05-22 |
20140142069 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF - The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders. | 2014-05-22 |
20140142070 | DARUNAVIR COMBINATION FORMULATIONS - This invention relates to solid oral dosage forms of the HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof. | 2014-05-22 |
20140142071 | REGRESSION OF ARTERIAL PLAQUE - Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation. | 2014-05-22 |
20140142072 | COMPOSITION COMPRISING A DIINDOLYLMETHANE AND A RETINOID TO TREAT A SKIN CONDITION - Provided is a composition for use in treating a skin condition, the composition comprising: (a) a first component comprising a substituted or unsubstituted diindolylmethane compound; and (b) a second component comprising a substituted or unsubstituted retinoid compound. | 2014-05-22 |
20140142073 | AQUEOUS BASED CAPSAICINOID FORMULATIONS AND METHODS OF MANUFACTURE AND USE - Capsaicinoid formulations and methods of treatment are disclosed herein which can be utilized to treat/attenuate pain in mammals. Typically, administration is via injection at a discrete site to provide pain relief for an extended period of time. The formulations are administered in a pharmaceutically acceptable vehicle. The formulations include an analgesic agent in an amount sufficient to attenuate the burning and hyperalgesic effects of capsaicinoid administration. The invention also includes a method of treating pain by administering a corticosteroid followed by administration of a capsaicinoid. | 2014-05-22 |
20140142074 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof. | 2014-05-22 |
20140142075 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT - Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention. | 2014-05-22 |
20140142076 | ORAL TRANSMUCOSAL DRUG DELIVERY SYSTEM - This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms. | 2014-05-22 |
20140142077 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION - The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject. | 2014-05-22 |
20140142078 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 2014-05-22 |
20140142079 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF - Disclosed are a class of platinum compounds with a leaving group of malonic acid derivatives containing amino and alkylamino, their pharmaceutically acceptable salts, their preparation methods and pharmaceutical composites comprising them. Disclosed also are for the uses of the compounds in the treatment of cell proliferative diseases, particularly for the treatment of cancers. The present platinum compounds have high water solubility and low toxicity. | 2014-05-22 |
20140142080 | NOVEL GOLD(III) COMPLEXES CONTAINING N-HETEROCYCLIC CARBENE LIGAND, SYNTHESIS, AND THEIR APPLICATIONS IN CANCER TREATMENT AND THIOL DETECTION - Provided herein is a method of synthesis of Au(III)-NHC complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Au(III)-NHC complexes. Also provided is method of detecting thiol in a biological system. The Au(III)-NHC complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo. | 2014-05-22 |
20140142081 | COMPOUNDS AND THEIR METHODS OF USE - Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer. | 2014-05-22 |
20140142082 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof. | 2014-05-22 |
20140142083 | Substituted Benzene Compounds - The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2014-05-22 |
20140142084 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND - Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. | 2014-05-22 |
20140142085 | COMPOUNDS FOR THE TREATMENT OF HIV - The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus. | 2014-05-22 |
20140142086 | Substituted Benzoazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease. | 2014-05-22 |
20140142087 | INHIBITORS OF PHOSPHATIDIC ACID PHOSPHOHYDROLASE (PAP), INCLUDING D-PROPRANOLOL AND ANALOGS THEREOF, ALONE OR IN COMBINATION WITH DESIPRAMINE, FOR THE TREATMENT OF CANCERS THAT DEPEND ON THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), ONCOGENIC VARIANTS THEREOF AND OTHER MEMBERS OF THE ErbB/HER FAMILY - Compounds and combinations of them that inhibit phosphatidic phosphohydrolase (PAP) enzymatic activity are formulated into pharmaceuticals useful in cancer treatment. Inhibitors of PAP can be used for blocking the progression of cancers that depend on the epidermal growth factor receptor (EGFR), its oncogenic variants and other members of its ErbB tyrosine kinase receptor family, through induction of their endocytosis, thus making them inaccessible to the extracellular stimuli that promote maintenance and progression of cancer. | 2014-05-22 |
20140142088 | PYRIDAZINONE DERIVATIVES - The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition. | 2014-05-22 |
20140142089 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME - A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease. | 2014-05-22 |
20140142090 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES - The present invention is directed to novel pyrrolobenzodiazepine dimers and methods of using the dimers in the treatment of proliferative diseases. | 2014-05-22 |
20140142091 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES - The present invention relates to a fused aminodihydrothiazine derivative of formula (I): | 2014-05-22 |
20140142092 | COMPOUNDS AND METHODS FOR SKIN REPAIR - The disclosure provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one mixed EP2/EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like. | 2014-05-22 |
20140142093 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS - The present invention relates to antibacterial compounds of formula (I) wherein “----” is a bond or is absent, V is CH, CR | 2014-05-22 |
20140142094 | KINASE INHIBITORS - This disclosure relates to compounds, methods for their preparation, pharmaceutical compositions including these compounds and methods for the treatment of cellular proliferative disorders, including, but not limited to cancer. The method includes administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. | 2014-05-22 |
20140142095 | AGENTS USEFUL FOR TREATING FRIEDREICH'S ATAXIA AND OTHER NEURODEGENERATIVE DISEASES - This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more systems of Friedreich's ataxia or other neurodegenerative disease. | 2014-05-22 |
20140142096 | Fused Substituted Aminopyrrolidine Derivative - A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure. | 2014-05-22 |
20140142097 | PYRIDINE-AND PYRAZINE DERIVATIVES - Compounds of the formula (I) in which R, R | 2014-05-22 |
20140142098 | TRIAZOLOPYRAZINE - Disclosed are compounds of the formula (I) | 2014-05-22 |
20140142099 | Purinone Derivatives as Tyrosine Kinase Inhibitors - The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof. | 2014-05-22 |
20140142100 | NEW MACROLIDES AND THEIR USE - The invention relates to macrolide compounds of formula (I), | 2014-05-22 |
20140142101 | CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB - Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers. | 2014-05-22 |
20140142102 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS - The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy. | 2014-05-22 |
20140142103 | Methods and Compositions for Modulating Rad51 and Homologous Recombination - The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation. | 2014-05-22 |
20140142104 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 2014-05-22 |
20140142105 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4. | 2014-05-22 |
20140142106 | METHOD FOR TREATING PERITONEAL FIBROSIS - The present invention provides a method for treating, preventing or reducing peritoneal fibrosis comprising administering to a subject in need thereof a pharmacologically effective dose of a type I cannabinoid receptor (CB | 2014-05-22 |
20140142107 | ANTIFUNGAL AGENTS AND USES THEREOF - Antimicrobial agents, compositions that include the agent(s) and use(s) thereof are provided. Also disclosed are screening assays for identifying antimicrobial agents. | 2014-05-22 |
20140142108 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2014-05-22 |